CAM
ALNY icon

Cresset Asset Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Cresset Asset Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1,675
Closed -$461K – 1770
2024
Q3 		$461K Buy
1,675
+296
+21% +$77.1K ﹤0.01% 1566
2024
Q2 		$335K Buy
+1,379
New +$218K ﹤0.01% 1657
2024
Q1 		– Sell
-1,616
Closed -$309K – 1900
2023
Q4 		$309K Buy
+1,616
New +$275K ﹤0.01% 1476
2022
Q1 		– Sell
-3,852
Closed -$654K – 989
2021
Q4 		$654K Buy
3,852
+1,402
+57% +$261K 0.01% 600
2021
Q3 		$463K Buy
2,450
+598
+32% +$112K 0.01% 653
2021
Q2 		$314K Buy
+1,852
New +$271K ﹤0.01% 743
2019
Q2 		– Sell
-62
Closed -$6K – 519
2019
Q1 		$6K Buy
62
+8
+15% +$669 ﹤0.01% 1287
2018
Q4 		$4K Buy
+54
New +$4.15K ﹤0.01% 1066

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Cresset Asset Management's ALNY Position: Q4 2024 in Review

Cresset Asset Management sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2024, closing a stake of 1,675 shares — an estimated $461K sold.

Cresset Asset Management first reported a position in ALNY in Q4 2018 and held it in 8 quarters. The position peaked at $654K in Q4 2021. 595 funds tracked by Wall St. Rank hold ALNY as of Q4 2024.

  • Cresset Asset Management reported no remaining Alnylam Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Cresset Asset Management sold 1,675 Alnylam Pharmaceuticals shares in Q4 2024, an estimated $461K.
  • Cresset Asset Management first reported a position in Alnylam Pharmaceuticals in Q4 2018 and held it in 8 quarters.
  • Cresset Asset Management's Alnylam Pharmaceuticals position peaked at $654K in Q4 2021.
  • 595 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2024.

Based on Cresset Asset Management's 13F filing for Q4 2024, filed 14 Feb 2025.